# OV329 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ov329

> The next catalyst for OV329, sponsored by Ovid Therapeutics Inc. (OVID), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for OV329?

The next catalyst for OV329, sponsored by Ovid Therapeutics Inc. (OVID), is its topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "The study is enrolling, and Ovid anticipates reading out topline data in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/ov329)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-072494, https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/ov329#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | OV329 |
| Codes | OV329 |
| Sponsor | Ovid Therapeutics Inc. (OVID) https://sec-api.dev/companies/ovid/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2022: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001628280-24-046868): "In December 2022, we initiated a Phase 1 SAD/MAD study in healthy volunteers for OV329, a next-generation GABA-aminotransferase inhibitor." https://www.sec.gov/Archives/edgar/data/1636651/000162828024046868/ovid-20240930.htm

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-03-11, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-024911): "•Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025" https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid2025q1exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-011839): "•Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerability" https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid2024q4exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-011839): "•Topline biomarker & safety data expected Q3 2025: Ovid added a higher dose cohort to its Phase 1 study, to increase dosing opportunities for future Phase 2 programs." https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid2024q4exhibit991.htm

### October 2, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-03-11, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-230409): "Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies." https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212dex991.htm
- SEC Form 10-Q (accession 0001636651-25-000012): "On October 3, 2025, we announced positive topline Phase 1 trial data for our next-generation GABA-aminotransferase inhibitor, OV329." https://www.sec.gov/Archives/edgar/data/1636651/000163665125000012/ovid-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-024911): "OV329, a next-generation GABA-AT inhibitor, is anticipated to readout topline results in Q3 2025." https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid2025q1exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-011839): "Topline results from this cohort is expected in Q3 2025, and will include findings regarding how OV329 performed in specific parameters of transcranial magnetic stimulation (TMS) and magnetic resonance spectroscopy (MRS)." https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid2024q4exhibit991.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-11-12, last confirmed 2026-03-18.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019045): "Ovid is engaged in regulatory conversations and currently anticipates initiating the Phase 2 study in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovidexhibit9912025_x10-k.htm
- Press release filed with the SEC (EX-99) (accession 0001636651-25-000011): "Ovid is in the process of seeking scientific advice with regulators across multiple regions and plans to initiate a Phase 2a clinical study in Q2 2026." https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/ovidexhibit9912025-q3.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-10, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-072494): "The study is enrolling, and Ovid anticipates reading out topline data in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ov329.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OV329 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ov329

```bibtex
@misc{secapidev_pdufa_ov329_20261116,
  title        = {OV329 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ov329}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ov329_20261116","title":"OV329 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ov329","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
